CytoMed Therapeutics Limited Rings the Closing Bell in Celebration of its IPO

About This Event

CytoMed Therapeutics Limited (Nasdaq: GDTC), a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel allogeneic cell-based immunotherapies for the treatment of human cancers, visits the Nasdaq MarketSite in Times Square. In honor of the occasion, Peter Choo Chee Kong, Chairman, rings the Closing Bell.

Nasdaq Originals Exclusive insights on the forces shaping the convergence of technology, business and sports. Explore